Literature DB >> 36042320

Altered neuronal activity in the ventromedial prefrontal cortex drives nicotine intake escalation.

Myriam Abarkan1, Giulia R Fois2, Caroline Vouillac-Mendoza2, Serge H Ahmed2, Karine Guillem3.   

Abstract

Nicotine addiction develops after prolonged drug use and escalation of drug intake. However, because of difficulties in demonstrating escalation of nicotine use in rats, its underlying neuroadaptations still remain poorly understood. Here we report that access to unusually high doses of nicotine (i.e., from 30 µg to 240 µg/kg/injection) for self-administration precipitated a rapid and robust escalation of nicotine intake and increased the motivation for the drug in rats. This nicotine intake escalation also induced long-lasting changes in vmPFC neuronal activity both before and during nicotine self-administration. Specifically, after escalation of nicotine intake, basal vmPFC neuronal activity increased above pre-escalation and control activity levels, while ongoing nicotine self-administration restored these neuronal changes. Finally, simulation of the restoring effects of nicotine with in vivo optogenetic inhibition of vmPFC neurons caused a selective de-escalation of nicotine self-administration.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Year:  2022        PMID: 36042320     DOI: 10.1038/s41386-022-01428-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  53 in total

1.  Neurobiological evidence for hedonic allostasis associated with escalating cocaine use.

Authors:  Serge H Ahmed; Paul J Kenny; George F Koob; Athina Markou
Journal:  Nat Neurosci       Date:  2002-07       Impact factor: 24.884

2.  Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.

Authors:  Neil E Paterson; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

Review 3.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

4.  Transition from moderate to excessive drug intake: change in hedonic set point.

Authors:  S H Ahmed; G F Koob
Journal:  Science       Date:  1998-10-09       Impact factor: 47.728

5.  Conditioned withdrawal drives heroin consumption and decreases reward sensitivity.

Authors:  Paul J Kenny; Scott A Chen; Osamu Kitamura; Athina Markou; George F Koob
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

6.  Early course of nicotine dependence in adolescent smokers.

Authors:  Chyke A Doubeni; George Reed; Joseph R Difranza
Journal:  Pediatrics       Date:  2010-05-03       Impact factor: 7.124

7.  Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.

Authors:  Sunmee Wee; Zhixia Wang; William L Woolverton; Luigi Pulvirenti; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

8.  CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats.

Authors:  Olivier George; Sandy Ghozland; Marc R Azar; Pietro Cottone; Eric P Zorrilla; Loren H Parsons; Laura E O'Dell; Heather N Richardson; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-05       Impact factor: 11.205

9.  Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis.

Authors:  Chitra D Mandyam; Sunmee Wee; Amelia J Eisch; Heather N Richardson; George F Koob
Journal:  J Neurosci       Date:  2007-10-17       Impact factor: 6.167

10.  Supply of a nondrug substitute reduces escalated heroin consumption.

Authors:  Magalie Lenoir; Serge H Ahmed
Journal:  Neuropsychopharmacology       Date:  2007-10-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.